- First human study of IMM-101 conducted in patients with an advanced form of the skin cancer, melanoma, which had spread beyond the primary site to confirm safety of the intended dose
- At the clinical investigator’s request, it was agreed that patients could continue to receive IMM-101 on a long-term basis. In order to provide continuous treatment for these patients they were offered inclusion to a Compassionate Use Programme.
- Of the 18 patients enrolled* in the original study, 9 remained alive in 2018, more than 8 years later, with 4 of those still participating in the follow-up trial
- As two-thirds of patients had Stage IV metastatic disease these survival figures exceeded expectations
* one additional patient enrolled but withdrew early due to ineligibility
Stebbing J et al. An intra-patient placebo-controlled phase I trial to evaluate the safety and tolerability of intradermal IMM‑101 in melanoma. Annals of Oncology 2012 23(5):1314-1319
Dalgliesh AG and Stebbing J. Poster presented at European Society of Medical Oncology (ESMO) Immuno-oncology meeting in Lausanne, Switzerland, 20-21 November 2015
FUSI A, DALGLEISH AG. Poster presented at 16th International Congress of the Society for Melanoma Research (SMR) meeting in Salt-Lake City, Utah. 20-23rd November 2019.